TGen Research - Investigators and Advisors

Research Faculty


	Profile


	Selected Publications

Henderson MC, Shaw YJ, Wang H, Han H, Hurley LH, Flynn G, Dorr RT, Von Hoff DD. UA62784, a novel inhibitor of centromere protein E kinesin-like protein Mol Cancer Ther, Jan;8(1):36-44. 2009.

Wang H, Stephens B, Von Hoff DD, Han H. Identification and characterization of a novel anticancer agent with selectivity against deleted in pancreatic cancer locus 4 (DPC4)-deficient pancreatic and colon cancer cells Pancreas, Jul;38(5):551-7. 2009.

Stephens B, Han H, Hostetter G, Demeure MJ, Von Hoff DD. Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells Mol Cancer Ther, Jan;7(1):202-10. 2008.

Baker AF, Koh MY, Williams RR, James B, Wang H, Tate WR, Gallegos A, Von Hoff DD, Han H, Powis G. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer Pancreas, Mar;36(2):178-86. 2008.

Balagurunathan Y, Morse DL, Hostetter G, Shanmugam V, Stafford P, Shack S, Pearson J, Trissal M, Demeure MJ, Von Hoff DD, Hruby VJ, Gillies RJ, Han H. Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer Mol Cancer Ther., Sep;7(9):3071-80. 2008.

Warner SL, Muñoz RM, Bearss DJ, Grippo P, Han H, Von Hoff DD. Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice Pancreas, Oct;37(3):e39-44.. 2008.

Chen S, Auletta T, Dovirak O, Hutter C, Kuntz K, El-Ftesi S, Kendall J, Han H, Von Hoff DD, Ashfaq R, Maitra A, Iacobuzio-Donahue CA, Hruban RH, Lucito R. Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification Cancer Biol Ther, Nov 21;7(11). 2008.

Zhu M, Gokhale VM, Szabo L, Munoz RM, Baek H, Bashyam S, Hurley LH, Von Hoff DD, Han H. Identification of a novel inhibitor of urokinase-type plasminogen activator Mol Cancer Ther, Apr;6(4):1348-56. 2007.

Wang H, Han H, Mousses S, Von Hoff DD. Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents Semin Oncol, Aug;33(4):513-20. 2006.

Warner SL, Bashyam S, Vankayalapati H, Bearss DJ, Han H, Mahadevan D, Von Hoff DD, Hurley LH. Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach Mol Cancer Ther, Jul;5(7):1764-73.. 2006.

Han H, Von Hoff DD. Aurora sheds light on head and neck squamous cell carcinoma Clin Cancer Res, Sep 1;12(17):5003-4. 2006.

Wang H, Han H, Von Hoff DD. Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells Cancer Res, Oct 1;66(19):9722-30. 2006.

Warner SL, Munoz RM, Stafford P, Koller E, Hurley LH, Von Hoff DD, Han H. Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells Mol Cancer Ther, Oct;5(10):2450-8. 2006.

Stephens BJ, Han H, Gokhale V, Von Hoff DD. PRL phosphatases as potential molecular targets in cancer Mol Cancer Ther, Nov;4(11):1653-61. 2005.

J. P. Gray, Jr, D. J. Bearss, H. Han, R. Nagle, M. Tsao, N. Dean, and D. D. Von Hoff. Identification of Human Polo-like Kinase 1 as a Potential Therapeutic Target in Pancreatic Cancer. Mol Cancer Ther, 3: 641-646. 2004.

S. Rojanala, H. Han, R. M. Munoz, W. Browne, R. Nagle and D. D. Von Hoff, D. J. Bearss. The Mitotic Serine Threonine Kinase, Aurora-2, is a Potential Target for Drug Development in Human Pancreatic Cancer. Mol. Cancer Ther., 3, 451-457. 2004.

S. L. Warner, D. J. Bearss, H. Han, D. D. Von Hoff. Targeting aurora-2 kinase in cancer. Mol. Cancer Ther., 2, 589-595. 2003.

H. Han, D. J. Bearss and L. W. Browne, R. Calaluce, R. B. Nagle, D. D. Von Hoff. Identification of Genes Differentially Expressed in Pancreatic Cancer Cells Using cDNA Microarray. Cancer Res., 62, 2890-2896. 2002.

C. L. Grand, H. Han, R. M. Munoz, S. Weitman, D. D. Von Hoff, L. H. Hurley, and D. J. Bearss. The Cationic Porphyrin TMPyP4 Downregulates c-MYC and hTERT Expression and Inhibits Tumor Growth in vivo. Mol. Cancer Ther., 1, 565-573. 2002.

H. Han, D. R. Langley, A. Rangan, L. H. Hurley. Selective Interaction of Cationic Porphyrins with Different Types of G-Quadruplex Structures. J. Am. Chem. Soc., 123, 8902-8913. 2001.

Duan W, Rangan A, Vankayalapati H, Kim MY, Zeng Q, Sun D, Han H, Fedoroff OY, Nishioka D, Rha SY, Izbicka E, Von Hoff DD, Hurley LH. Design and synthesis of fluoroquinophenoxazines that interact with human telomeric G-quadruplexes and their biological effects Mol Cancer Ther, Dec;1(2):103-20. 2001.

H. Han, L. H. Hurley. G-quadruplex: a Potential Target for Anticancer Drug Design. Trends Pharmacol. Sci., 21, 136-142. 2000.

Han H, Bennett RJ, Hurley LH. Inhibition of unwinding of G-quadruplex structures by Sgs1 helicase in the presence of N,N'-bis[2-(1-piperidino)ethyl]-3,4,9,10-perylenetetracarboxylic diimide, a G-quadruplex-interactive ligand Biochemistry, Aug 8;39(31):9311-6. 2000.

Hurley LH, Wheelhouse RT, Sun D, Kerwin SM, Salazar M, Fedoroff OY, Han FX, Han H, Izbicka E, Von Hoff DD. G-quadruplexes as targets for drug design Pharmacol Ther, Mar;85(3):141-58. 2000.

Han H, Hurley LH, Salazar M. A DNA polymerase stop assay for G-quadruplex-interactive compounds Nucleic Acids Res, Jan 15;27(2):537-42. 1999.

Han H, Cliff CL, Hurley LH. Accelerated assembly of G-quadruplex structures by a small molecule Biochemistry, Jun 1;38(22):6981-6. 1999.